Benefits of Strict Glucose and Blood Pressure Control in Type 2 Diabetes
1999; Lippincott Williams & Wilkins; Volume: 99; Issue: 4 Linguagem: Inglês
10.1161/01.cir.99.4.461
ISSN1524-4539
Autores Tópico(s)Pharmacology and Obesity Treatment
ResumoHomeCirculationVol. 99, No. 4Benefits of Strict Glucose and Blood Pressure Control in Type 2 Diabetes Free AccessOtherPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessOtherPDF/EPUBBenefits of Strict Glucose and Blood Pressure Control in Type 2 Diabetes Lessons From the UK Prospective Diabetes Study Markku Laakso Markku LaaksoMarkku Laakso From the Department of Medicine, University of Kuopio, Kuopio, Finland. Originally published2 Feb 1999https://doi.org/10.1161/01.CIR.99.4.461Circulation. 1999;99:461–462For decades, the treatment of type 2 diabetes has been based more on assumptions than on facts. Even the most crucial question—does a reduction in blood glucose help to prevent long-term complications—has remained unanswered. Now, 4 reports from the United Kingdom Prospective Diabetes Study (UKPDS)1234 offer useful information on the benefits of treating hyperglycemia and hypertension in this disorder.Whereas the complications of type 1 diabetes are chiefly microvascular, patients with type 2 diabetes are prone to accelerated atherosclerosis.5 The most important macrovascular complication is coronary heart disease (CHD), which causes almost half the deaths in these patients. Although classic risk factors (ie, high total cholesterol, hypertension, and smoking) play a substantial part in pathogenesis, they do not explain the excess of macrovascular complications in type 2 diabetes. Therefore, the specific risk factors, particularly hyperglycemia, have been given increasing attention. In population-based prospective studies, hyperglycemia has indeed proved to be associated with risk of CHD in type 2 diabetes: a 1% change in glycohemoglobin (HbA1c) signifies about a 10% change in risk of CHD.67 Thus, there is potential, albeit modest, for reducing CHD events by lowering blood glucose.Control of HyperglycemiaWhat is the evidence that improvement in glycemic control is beneficial in this respect? The first study aiming to address this question, the University Group Diabetes Program (UGDP), published in the 1970s,8 randomized ≈200 patients with type 2 diabetes to phenformin, tolbutamide, a fixed insulin dose, a variable insulin dose, or placebo. With phenformin and tolbutamide, cardiovascular mortality was higher than with insulin or placebo (for which the rates were about the same), and a suspicion that oral hypoglycemic agents are harmful has persisted ever since. The UGDP did not answer the question whether improvement of glycemic control prevents complications.The UKPDS, which began in 1977, was designed to show whether intensive blood glucose control reduces the risk of macrovascular or microvascular complications and whether any particular therapy is advantageous. In that study, 3867 newly diagnosed patients with type 2 diabetes (median age, 54 years), who after 3 months' dietary treatment had a fasting plasma glucose of 6.1 to 15.0 mmol/L, were randomly assigned to an intensive-treatment policy (sulfonylurea or insulin, the sulfonylureas being chlorpropamide, glibenclamide, or glipizide) or to a conventional-treatment policy with diet. Over 10 years, HbA1c was 7.0% in the intensive-treatment group and 7.9% in the conventional-treatment group, an 11% difference, although glycemic control deteriorated almost linearly over time in both groups. Compared with the conventional-treatment group, the intensive-treatment group showed the following: any diabetes related end point, 12% reduction (P=0.029); death related to diabetes, 10% reduction (P=0.34); myocardial infarction, 16% reduction (P=0.052); stroke, 11% increase (P=0.52); microvascular disease, 25% reduction (P=0.0099).All-cause mortality rates did not differ significantly. Chlorpropamide, glibenclamide, and insulin were approximately equivalent in their benefits. There was no evidence of any glycemic threshold for either microvascular or macrovascular complications.These results leave no doubt that in type 2 diabetes, complication rates are lessened by reduction of blood glucose. Moreover, in obese patients (n=1704), treatment with metformin showed greater advantages over conventional treatment: a 32% reduction of diabetes-related end points (P=0.002), a 42% reduction of diabetes-related deaths (P=0.017), and a 36% reduction of all-cause mortality (P=0.011). Patients taking metformin also had less weight gain and fewer hypoglycemic attacks than those taking insulin or sulfonylureas.Control of HypertensionThe prevalence of hypertension in type 2 diabetes is >50% (twice that in the nondiabetic population), and subgroup analyses of large trials indicate that the benefits of treatment apply to diabetic patients. The UKPDS is the first large-scale trial to specifically examine the effects of intensive blood pressure lowering on the morbidity and mortality of hypertensive patients with type 2 diabetes. This investigation was superimposed on the project 10 years behind the glycemia study. Of 1148 patients (mean blood pressure at entry, 160/94 mm Hg), 758 were allocated to tight control (blood pressure <150/85 mm Hg) and 390 to less-tight control. The main treatments were captopril and atenolol. During the 8.4-year follow-up, mean blood pressure in the tightly controlled group was 144/82 mm Hg compared with 154/87 mm Hg in the less-tightly controlled group. The risks in the tightly controlled group were substantially lessened: any diabetes-related end point, 24% reduction (P=0.0046); death related to diabetes, 32% reduction (P=0.019); myocardial infarction, 21% reduction (P=0.13); stroke, 44% reduction (P=0.013); microvascular disease, 37% reduction (P=0.0092).As in the glycemia study, all-cause mortality rates showed no significant difference. Captopril and atenolol were equally effective both in lowering blood pressure and in reducing the incidence of diabetic complications; in other words, what matters most is the reduction rather than the nature of the agent prescribed.Implications of UKPDSFrom the above results, one might gain the impression that for reduction of all end points, even microvascular disease, blood pressure control is more beneficial than blood glucose control. We should not forget, however, that the number of patients in the hypertension trial was only one third the number in the glycemia trial and that the hypertension trial started 10 years later; therefore, the percentage reductions are not directly comparable. Of great interest are the results for stroke: whereas rigorous antihypertensive treatment lowered the risk as expected, no benefit was seen from blood glucose control. This came as a surprise because earlier prospective studies had indicated that hyperglycemia predicts stroke events more strongly than it does CHD events. Stricter control of blood pressure did not significantly reduce the risk of myocardial infarction, and the reduction achieved with intensive blood glucose control was of borderline significance.What have we learned from UKPDS? First, it offers powerful support for the "glucose toxicity" hypothesis in type 2 diabetes, viz, that hyperglycemia is causally related to microvascular and macrovascular complications and that intensive control of hyperglycemia is beneficial. However, glucose control deteriorated over time, and the treatment goal (fasting plasma glucose 65 years old, and 40% have symptoms of CHD or have experienced CHD events; also, blood glucose levels are commonly higher than the 6.1 mmol/L cut-off in the trial. UKPDS does not provide definite answers on how to treat such patients; although insulin and sulfonylureas gave equal benefits in the trial, we cannot be sure that this would be the case in elderly patients, particularly those with macrovascular complications. Moreover, the question whether metformin is superior to other agents in obese patients remains open; metformin was compared with all intensive treatments combined, not separately with insulin and sulfonylureas. An unexpected and unexplained finding was a 96% increase in diabetes-related death (P=0.039) in a group that received additional metformin after starting a sulfonylurea. Finally, UKPDS did not clarify the role of all possible combinations of therapy; for example, insulin plus metformin might be advantageous because weight gain is prevented.An important message from UKPDS and other recent trials is that if one seeks to prevent cardiovascular complications in type 2 diabetes, it is unwise to focus on single risk factors. All known risk factors should be attacked simultaneously. Intensive treatment of dyslipidemia9 and high blood pressure, in addition to hyperglycemia, should now be the rule.FootnotesCorrespondence to Markku Laakso, MD, Professor and Chair, Department of Medicine, University of Kuopio, 70210 Kuopio, Finland. E-mail [email protected] References 1 UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet.1998; 352:837–853.CrossrefMedlineGoogle Scholar2 UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet.1998; 352:854–865.CrossrefMedlineGoogle Scholar3 UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ.1998; 317:703–713.CrossrefMedlineGoogle Scholar4 UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ.1998; 317:713–720.CrossrefMedlineGoogle Scholar5 Laakso M, Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes Reviews.1997; 5:294–315.Google Scholar6 Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care.1995; 18:258–268.CrossrefMedlineGoogle Scholar7 Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, Holman RR, for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ.1998; 316:823–828.CrossrefMedlineGoogle Scholar8 University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes, V: evaluation of phenformin therapy. Diabetes. 1975;24(suppl 1):65–184.Google Scholar9 Pyörälä K, Pederson TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G, for the Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary artery disease. Diabetes Care.1997; 20:614–620.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By AbuRahma A, Avgerinos E, Chang R, Darling R, Duncan A, Forbes T, Malas M, Perler B, Powell R, Rockman C and Zhou W (2022) The Society for Vascular Surgery implementation document for management of extracranial cerebrovascular disease, Journal of Vascular Surgery, 10.1016/j.jvs.2021.04.074, 75:1, (26S-98S), Online publication date: 1-Jan-2022. Giokas K, Iliopoulou D, Koutsouri G and Koutsouris D (2019) Health Guidance Provision Infrastructure for Personalized Diabetes Management Healthcare Policy and Reform, 10.4018/978-1-5225-6915-2.ch023, (475-492) Giokas K, Iliopoulou D, Koutsouri G and Koutsouris D (2019) Health Guidance Provision Infrastructure for Personalized Diabetes Management Chronic Illness and Long-Term Care, 10.4018/978-1-5225-7122-3.ch019, (378-395) Orssaud C (2019) Les complications ophtalmologiques du diabète, Revue Francophone d'Orthoptie, 10.1016/j.rfo.2019.04.013, 12:2, (77-84), Online publication date: 1-Apr-2019. Van Steenbergen A, Balteau M, Ginion A, Ferté L, Battault S, Ravenstein C, Balligand J, Daskalopoulos E, Gilon P, Despa F, Despa S, Vanoverschelde J, Horman S, Koepsell H, Berry G, Hue L, Bertrand L and Beauloye C (2017) Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart, Scientific Reports, 10.1038/srep41166, 7:1, Online publication date: 1-Mar-2017. Lal B and Cires-Drouet R (2017) Cerebrovascular Disease in the Elderly Vascular Disease in Older Adults, 10.1007/978-3-319-29285-4_6, (113-125), . Giokas K, Iliopoulou D, Koutsouri G and Koutsouris D (2016) Health Guidance Provision Infrastructure for Personalized Diabetes Management Handbook of Research on Trends in the Diagnosis and Treatment of Chronic Conditions, 10.4018/978-1-4666-8828-5.ch017, (365-381) Ooi C and Loke S (2013) Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review*, Diabetic Medicine, 10.1111/dme.12295, 31:1, (2-14), Online publication date: 1-Jan-2014. Brott T, Halperin J, Abbara S, Bacharach J, Barr J, Bush R, Cates C, Creager M, Fowler S, Friday G, Hertzberg V, McIff E, Moore W, Panagos P, Riles T, Rosenwasser R, Taylor A, Jacobs A, Smith S, Anderson J, Adams C, Albert N, Buller C, Creager M, Ettinger S, Guyton R, Halperin J, Hochman J, Hunt S, Krumholz H, Kushner F, Lytle B, Nishimura R, Ohman E, Page R, Riegel B, Stevenson W, Tarkington L and Yancy C (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive summary, Catheterization and Cardiovascular Interventions, 10.1002/ccd.22983, 81:1, (E76-E123), Online publication date: 1-Jan-2013. Constantinou J, Jayia P and Hamilton G (2013) Best evidence for medical therapy for carotid artery stenosis, Journal of Vascular Surgery, 10.1016/j.jvs.2013.06.085, 58:4, (1129-1139), Online publication date: 1-Oct-2013. Chilton R (2013) Trading Glucose Control for Hypertension: Lessons from Mother Nature, Clinical Diabetes, 10.2337/diaclin.31.1.21, 31:1, (21-24), Online publication date: 1-Jan-2013. Yamashita T, Kart C and Noe D (2011) Predictors of adherence with self-care guidelines among persons with type 2 diabetes: results from a logistic regression tree analysis, Journal of Behavioral Medicine, 10.1007/s10865-011-9392-y, 35:6, (603-615), Online publication date: 1-Dec-2012. Brott T, Halperin J, Abbara S, Bacharach J, Barr J, Bush R, Cates C, Creager M, Fowler S, Friday G, Hertzberg V, McIff E, Moore W, Panagos P, Riles T, Rosenwasser R and Taylor A (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease, Journal of the American College of Cardiology, 10.1016/j.jacc.2010.11.006, 57:8, (e16-e94), Online publication date: 1-Feb-2011. Brott T, Halperin J, Abbara S, Bacharach J, Barr J, Bush R, Cates C, Creager M, Fowler S, Friday G, Hertzberg V, McIff E, Moore W, Panagos P, Riles T, Rosenwasser R and Taylor A (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/ SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary, Vascular Medicine, 10.1177/1358863X11399328, 16:1, (35-77), Online publication date: 1-Feb-2011. Ricotta J, AbuRahma A, Ascher E, Eskandari M, Faries P and Lal B (2011) Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease, Journal of Vascular Surgery, 10.1016/j.jvs.2011.07.031, 54:3, (e1-e31), Online publication date: 1-Sep-2011. de Lorgeril M and Salen P (2011) Dietary Intervention in Coronary Care Units and in Secondary Prevention Acute Coronary Syndromes: A Companion to Braunwald's Heart Disease, 10.1016/B978-1-4160-4927-2.00031-1, (344-360), . Brott T, Halperin J, Abbara S, Bacharach J, Barr J, Bush R, Cates C, Creager M, Fowler S, Friday G, Hertzberg V, McIff E, Moore W, Panagos P, Riles T, Rosenwasser R and Taylor A (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary, Journal of the American College of Cardiology, 10.1016/j.jacc.2010.11.005, 57:8, (1002-1044), Online publication date: 1-Feb-2011. Brott T, Halperin J, Abbara S, Bacharach J, Barr J, Bush R, Cates C, Creager M, Fowler S, Friday G, Hertzberg V, McIff E, Moore W, Panagos P, Riles T, Rosenwasser R and Taylor A (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary, Circulation, 124:4, (489-532), Online publication date: 26-Jul-2011.Brott T, Halperin J, Abbara S, Bacharach J, Barr J, Bush R, Cates C, Creager M, Fowler S, Friday G, Hertzberg V, McIff E, Moore W, Panagos P, Riles T, Rosenwasser R and Taylor A (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary, Stroke, 42:8, (e420-e463), Online publication date: 1-Aug-2011.Brott T, Halperin J, Abbara S, Bacharach J, Barr J, Bush R, Cates C, Creager M, Fowler S, Friday G, Hertzberg V, McIff E, Moore W, Panagos P, Riles T, Rosenwasser R and Taylor A (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease, Circulation, 124:4, (e54-e130), Online publication date: 26-Jul-2011.Brott T, Halperin J, Abbara S, Bacharach J, Barr J, Bush R, Cates C, Creager M, Fowler S, Friday G, Hertzberg V, McIff E, Moore W, Panagos P, Riles T, Rosenwasser R and Taylor A (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease, Stroke, 42:8, (e464-e540), Online publication date: 1-Aug-2011. Al Mazroui N, Kamal M, Ghabash N, Yacout T, Kole P and McElnay J (2009) Influence of pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus, British Journal of Clinical Pharmacology, 10.1111/j.1365-2125.2009.03391.x, 67:5, (547-557), Online publication date: 1-May-2009. Shammas N, Sica D and Toth P (2012) A Guide to the Management of Blood Pressure in the Diabetic Hypertensive Patient, American Journal of Cardiovascular Drugs, 10.1007/BF03256572, 9:3, (149-162), Online publication date: 1-Jun-2009. Doggrell S (2008) Clinical trials with thiazolidinediones in subjects with Type 2 diabetes – is pioglitazone any different from rosiglitazone?, Expert Opinion on Pharmacotherapy, 10.1517/14656566.9.3.405, 9:3, (405-420), Online publication date: 1-Feb-2008. Genuth S (2008) The UKPDS and its global impact, Diabetic Medicine, 10.1111/j.1464-5491.2008.02504.x, 25, (57-62), Online publication date: 1-Aug-2008. Singer G, Setaro J and Black H (2007) Goal-Oriented Hypertension Management in Diabetic and Nondiabetic Patients Hypertension and Hormone Mechanisms, 10.1007/978-1-59259-987-5_13, (205-222), . Singer G and Setaro J Management of Hypertension Preventive Cardiology, 10.1007/978-1-59745-096-6_6, (93-112) Rodrigues T, Pecis M, Azevedo M and Gross J (2005) Homeostase pressórica e complicações microvasculares em pacientes diabéticos, Arquivos Brasileiros de Endocrinologia & Metabologia, 10.1590/S0004-27302005000600005, 49:6, (882-890), Online publication date: 1-Dec-2005. Snchez Rodrguez A, Snchez Ledesma M and Cruz Gonzlez I (2005) Hipertensi?n arterial. Relevancia epidemiol?gica. Tratamiento farmacol?gico. Indicaciones. Criterios de respuesta. Asociaciones. Efectos secundarios. Interacciones. Situaciones de especial relevancia, Medicine - Programa de Formaci?n M?dica Continuada Acreditado, 10.1016/S0211-3449(05)73852-2, 9:46, (3050-3061), Online publication date: 1-Nov-2005. Dr Ascaso J (2004) Diabetes mellitus y riesgo cardiovascular. Recomendaciones del Grupo de Trabajo Diabetes Mellitus y Enfermedad Cardiovascular de la Sociedad Española de Diabetes, Clínica e Investigación en Arteriosclerosis, 10.1016/S0214-9168(04)78963-9, 16:2, (74-78), Online publication date: 1-Jan-2004. de Lorgeril M and Salen P (2004) Diet and the prevention of coronary heart disease Functional Foods, Cardiovascular Disease and Diabetes, 10.1533/9781855739499.1.21, (21-55), . Pater C, Bhatnagar D, Berrou J, Luszick J and Beckmann K (2004) A novel approach to treatment of hypertension in diabetic patients – a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 – rationale and design [ISRCTN55725285], Current Controlled Trials in Cardiovascular Medicine, 10.1186/1468-6708-5-9, 5:1, Online publication date: 1-Dec-2004. Tenenbaum A and Fisman E (2004) Impaired Glucose Metabolism in Patients with Heart Failure, American Journal of Cardiovascular Drugs, 10.2165/00129784-200404050-00001, 4:5, (269-280), . Ali Raza J and Movahed A (2003) Current concepts of cardiovascular diseases in diabetes mellitus, International Journal of Cardiology, 10.1016/S0167-5273(02)00510-7, 89:2-3, (123-134), Online publication date: 1-Jun-2003. Ragucci E, Zonszein J and Frishman W (2003) Pharmacotherapy of Diabetes Mellitus: Implications for the Prevention and Treatment of Cardiovascular Disease, Heart Disease, 10.1097/01.HDX.0000050411.62103.F5, 5:1, (18-33), Online publication date: 1-Jan-2003. Reynolds H and Deedwania P (2002) Treating Hypertension in Patients with Diabetes, The Nurse Practitioner, 10.1097/00006205-200207000-00003, 27:7, (11-15), Online publication date: 1-Jul-2002. Ihlemann N, Stokholm K and Eskildsen P (2002) Impaired vascular reactivity is present despite normal levels of von Willebrand factor in patients with uncomplicated Type 2 diabetes, Diabetic Medicine, 10.1046/j.1464-5491.2002.00715.x, 19:6, (476-481), Online publication date: 1-Jun-2002. Scherpereel P and Tavernier B (2001) Perioperative care of diabetic patients, European Journal of Anaesthesiology, 10.1097/00003643-200105000-00002, 18:5, (277-294), Online publication date: 1-May-2001. Henry R (2001) Preventing Cardiovascular Complications of Type 2 Diabetes: Focus on Lipid Management, Clinical Diabetes, 10.2337/diaclin.19.3.113, 19:3, (113-120), Online publication date: 1-Jul-2001. Scherpereel P and Tavernier B (2001) Perioperative care of diabetic patients, European Journal of Anaesthesiology, 10.1046/j.0265-0215.2001.00876.x, 18:5, (277-294), Online publication date: 1-May-2001. de Lorgeril M and Salen P (2000) Diet as preventive medicine in cardiology, Current Opinion in Cardiology, 10.1097/00001573-200009000-00009, 15:5, (364-370), Online publication date: 1-Sep-2000. Kaski J and Smith D (2007) The Management of Chronic Ischemic Heart Disease in the Elderly, The American Journal of Geriatric Cardiology, 10.1111/j.1076-7460.2000.80024.x, 9:3, (145-151), Online publication date: 1-May-2000. Davidson J (2000) Introduction, Endocrine Practice, 10.4158/EP.6.1.86, 6:1, (86-87), Online publication date: 1-Jan-2000. Laakso M (2000) Hyperglycemia and cardiovascular disease in patients with type 2 diabetes, Current Opinion in Endocrinology & Diabetes, 10.1097/00060793-200008000-00004, 7:4, (197-202), Online publication date: 1-Aug-2000. Simons L, Friedlander Y, McCallum J and Simons J (2008) Fasting plasma glucose in non-diabetic elderly women predicts increased all-causes mortality and coronary heart disease risk, Australian and New Zealand Journal of Medicine, 10.1111/j.1445-5994.2000.tb01053.x, 30:1, (41-47), Online publication date: 1-Feb-2000. Marks J and Raskin P (2000) Cardiovascular risk in diabetes, Journal of Diabetes and its Complications, 10.1016/S1056-8727(00)00065-9, 14:2, (108-115), Online publication date: 1-Mar-2000. Standl E (1999) Cardiovascular risk in type 2 diabetes, Diabetes, Obesity and Metabolism, 10.1046/j.1463-1326.1999.0010s2024.x, 1:s2, (24-36), Online publication date: 1-Sep-1999. Ooi C and Loke S (2012) Colesevelam for type 2 diabetes mellitus, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD009361.pub2 Ruyatkina L and Ruyatkin D (2017) Multidimensional effects of metformin in patients with type 2 diabetes, Diabetes mellitus, 10.14341/DM2003458-64, 20:3, (210-219) February 2, 1999Vol 99, Issue 4 Advertisement Article InformationMetrics Copyright © 1999 by American Heart Associationhttps://doi.org/10.1161/01.CIR.99.4.461 Originally publishedFebruary 2, 1999 PDF download Advertisement
Referência(s)